Experts at the 2025 ICE-T Symposium reviewed CAR T-cell therapy, bispecific antibodies, and gene therapy across myeloma, lymphoma, autoimmune disease, and solid tumors, emphasizing safety and access.
Anas Zayad, MD, PGY-1
Advertisement
Articles by Anas Zayad, MD, PGY-1
The 2025 ICE-T Symposium highlighted expansion beyond BCMA to additional targets such as GPRC5D and FcRH5.
Advertisement
Latest Updated Articles
The Next Frontier of Cellular Therapy in OncologyOctober 28th 2026
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Where Does Prostate Brachytherapy Fit Best in the Treatment Paradigm?
5